Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer
The overall survival expectancy of localized gastroesophageal cancer patients still remains under 5 years despite advances in neoadjuvant and adjuvant treatment strategies in recent years. For almost a decade, immunotherapy has been successfully implemented as a first-line treatment for various onco...
Main Authors: | Hannah Christina Puhr, Thorsten J. Reiter, Matthias Preusser, Gerald W. Prager, Aysegül Ilhan-Mutlu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/6/1900 |
Similar Items
-
New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
by: Hannah Christina Puhr, et al.
Published: (2020-01-01) -
Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
by: Hannah Christina Puhr, et al.
Published: (2021-09-01) -
Therapeutic Advances in the Treatment of Gastroesophageal Cancers
by: Jenny J. Li, et al.
Published: (2023-05-01) -
The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer
by: Colum Dennehy, et al.
Published: (2024-01-01) -
(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences
by: Thomas Zander, et al.
Published: (2022-02-01)